Dane Leone
Stock Analyst at Raymond James
(1.18)
# 3,769
Out of 5,124 analysts
69
Total ratings
33.96%
Success rate
-6.35%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $8.12 | +133.99% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.71 | +467.21% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $14.03 | +220.74% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $79.45 | -62.24% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $775.14 | +22.56% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $1.95 | +568.38% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $72.07 | -36.17% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $32.63 | +111.46% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $4.82 | +65.98% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $11.06 | +26.58% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $14.02 | +313.69% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $18.93 | +269.78% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.42 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $63.03 | -0.05% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $54.37 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.01 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $79.47 | -18.21% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $326.27 | -21.84% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.97 | +706.05% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $205.57 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $8.12
Upside: +133.99%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.71
Upside: +467.21%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $14.03
Upside: +220.74%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $79.45
Upside: -62.24%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $775.14
Upside: +22.56%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $1.95
Upside: +568.38%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $72.07
Upside: -36.17%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $32.63
Upside: +111.46%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $4.82
Upside: +65.98%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $11.06
Upside: +26.58%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $14.02
Upside: +313.69%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $18.93
Upside: +269.78%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.42
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $63.03
Upside: -0.05%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $54.37
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.01
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $79.47
Upside: -18.21%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $326.27
Upside: -21.84%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.97
Upside: +706.05%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $205.57
Upside: -